Study adds evidence for more targeted BRD antibiotic use: full analysis

A new Scientific Reports study is sharpening the conversation around antibiotic use in beef cattle by asking a question veterinarians confront every receiving season: which animals actually need metaphylaxis, and which are being treated just in case? Researchers from Texas A&M University, Mississippi State University, and West Texas A&M University reported that whole-blood gene expression at the onset of bovine respiratory disease, or BRD, showed strong and consistent immune and inflammatory signals, but their 2026 cohort did not yield a reliable at-arrival transcriptomic predictor of which high-risk stocker heifers would later become clinical cases. (nature.com)

The study sits within a larger, multiyear effort to make BRD management less subjective. BRD remains the leading cause of morbidity in North American feedlots and the leading reason for antimicrobial use in U.S. feedlots. In practice, veterinarians often rely on broad risk categories to decide whether cattle should receive metaphylaxis on arrival, but recent survey work shows wide variation in how professionals classify medium-risk groups and when they think preventive treatment is warranted. That variability is exactly why researchers and industry groups have been pushing for more objective risk assessment tools. (nature.com)

In the new paper, 84 commercial heifers were randomly assigned to tulathromycin metaphylaxis or no metaphylaxis at arrival, and a subset of 60 animals underwent RNA sequencing across multiple timepoints during a 70-day follow-up. The authors reported minimal transcriptomic differences between metaphylaxis and no-metaphylaxis animals at the time BRD was diagnosed. By contrast, when they compared healthy cattle with animals at the onset of clinical BRD, they found more than 2,000 differentially expressed genes, with enrichment in cytokine signaling, lymphocyte activation, and inflammatory pathways. Five genes, IL1R2, HP, S100A9, TLR4, and ALOX15, emerged as consistent signals across groups, suggesting they may be useful biomarker candidates. The authors also noted that heat shock protein expression at later treatments may help flag persistent or more severe disease. (nature.com)

What makes the findings especially interesting is how they fit with the same research network’s earlier work. A prior time-course transcriptomic study in high-risk beef cattle found that at-arrival gene expression could distinguish cattle that stayed healthy from those later treated multiple times or lost to BRD, with differences tied to specialized pro-resolving mediator pathways, complement, and immune regulation. Program summaries from the NC1192 multistate BRD project also reported that, in another randomized metaphylaxis trial, cattle that eventually developed BRD showed no gene expression differences by metaphylaxis status, while transcriptomic changes at treatment reflected increased neutrophil degranulation and reduced pro-resolving immune pathways. Taken together, the evidence suggests the biology is real, but the predictive signal may depend heavily on cohort characteristics, morbidity pressure, and study design. (pmc.ncbi.nlm.nih.gov)

There’s also a stewardship backdrop here that veterinary professionals can’t ignore. A recent systematic review described BRD as the most common disease in North American feedlots and framed antimicrobial resistance in BRD pathogens as a growing concern. Separate work from Mississippi State has linked tulathromycin metaphylaxis in high-risk stocker cattle with increased isolation of multidrug-resistant Mannheimia haemolytica. None of that means metaphylaxis should be abandoned in clearly high-risk populations; in fact, the literature the new paper cites still supports its value in reducing BRD morbidity and mortality. But it does increase pressure to reserve mass treatment for cattle most likely to benefit. (pmc.ncbi.nlm.nih.gov)

Why it matters: For veterinarians, this is less about a single biomarker panel being ready for chute-side use and more about the direction of travel. The field is moving toward objective, biology-based risk classification, whether through transcriptomics, metabolomics, hematology, or combined models. If those tools can reliably sort cattle at arrival, they could help reduce unnecessary antimicrobial exposure, preserve drug efficacy, and give veterinarians a stronger evidence base for stewardship decisions without giving up disease control in truly high-risk groups. USDA project reporting from Texas A&M has already pointed to ongoing work in transcriptomics and metabolomics aimed at exactly that kind of targeted metaphylaxis framework. (portal.nifa.usda.gov)

What to watch: The next important step is external validation, especially in larger cohorts with higher morbidity, where predictive performance can be tested under real commercial conditions. Watch, too, for whether these candidate genes are translated into practical assays, and whether future studies combine transcriptomic signals with management data, vaccination history, or pathogen testing to improve decision-making at arrival. The key question for the industry isn’t whether stewardship matters, but whether science can deliver a tool that’s accurate, affordable, and usable at processing speed. (nature.com)